The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase IB study of olaparib (AZD2281) plus gefitinib in EGFR-mutant patients (p) with advanced non-small-cell lung cancer (NSCLC) (NCT01513174/GECP-GOAL).
Rosario GarcĂ­a Campelo
No relevant relationships to disclose
Enriqueta Felip
No relevant relationships to disclose
Bartomeu Massuti
No relevant relationships to disclose
Margarita Majem
No relevant relationships to disclose
Enric Carcereny
No relevant relationships to disclose
Felipe Cardenal
No relevant relationships to disclose
Miguel Angel Molina-Vila
No relevant relationships to disclose
Alex Martinez Marti
No relevant relationships to disclose
Juan Luis Marti-Ciriquian
No relevant relationships to disclose
Guillermo Alonso-Jaudenes Curbera
No relevant relationships to disclose
Cinta Pallares
No relevant relationships to disclose
Ramon Palmero
No relevant relationships to disclose
Maria Carmen Gonzalez-Arenas
No relevant relationships to disclose
Clara Mayo-de las Casas
No relevant relationships to disclose
Maria Sanchez-Ronco
No relevant relationships to disclose
Rafael Rosell
No relevant relationships to disclose